How gut inflammation rewires the ‘second brain’—and why it lasts

Milena Bogunovic’s team at Massachusetts General Hospital didn’t set out to explain why some IBD patients develop chronic motility disorders. They found it by accident—while mapping how intestinal nerves reorganize after inflammation. Their study, published in the Journal of Experimental Medicine, reveals that even after inflammation subsides, the enteric nervous system (the ‘second brain’) retains a altered wiring pattern, permanently changing how muscles contract.

The implications stretch beyond academic curiosity. Functional motility disorders like IBS affect 10–15% of the global population, yet their roots remain poorly understood. This work provides the first mechanistic link between acute inflammation and lasting dysfunction—not by damaging tissue, but by rewiring the nerves that control it.

Critically, the study used both mouse models and human tissue samples, a dual approach that strengthens its relevance. But as Bogunovic notes, ‘We’ve identified how this happens—not how to reverse it.’ That distinction matters for patients reading headlines today.

The research hinged on a surprising observation: inflammatory signals don’t just activate immune cells—they instruct neuronal support cells (glia) to reshape nerve circuits. In mice, this led to persistent muscle contraction patterns even after inflammation resolved. Human colon samples from IBD patients showed the same glial activation markers, suggesting the mechanism translates across species.

Yet the study’s scope has clear limits. It’s an observational mechanistic study, not a clinical trial. The mouse models used dextran sulfate sodium to induce colitis—a standard but imperfect proxy for human IBD. And while the nerve changes persisted, the team didn’t test whether they could be reversed with existing drugs like GLP-1 agonists, now being explored for IBS.

For patients, this changes nothing yet. But it does validate a long-suspected theory: that IBS isn’t just a ‘functional’ disorder with no physical cause, but a lasting consequence of inflammation’s invisible rewiring. The next step? Targeting glial cells to prevent—or undo—that rewiring.